Summary Young age at diagnosis is claimed to be a prognostic factor in the natural history of breast cancer. Of 2879 patients aged < 70 years treated for primary operable breast cancer (< 5 cm diameter) at Nottingham City Hospital between 1973 and 1993, 120 were less than 35 years of age at diagnosis. Histopathological and prognostic variables were compared between patients aged < 35, 35-50 and 51-70 years. A significant reduction in metastasis disease-free survival and actuarial survival was seen in breast cancer patients aged < 35 years compared with the two older age groups. Patients aged < 35 years at diagnosis presented more frequently with high-grade cancers and vascular invasion. No differences were seen for tumour size or lymph node stage. The Nottingham Prognostic Index (NPI) was used to stratify cancers in each age group. Because of the tendency to high grade, a greater percentage of patients aged < 35 years fell into the poorprognosis group. Within each prognostic group, no difference in actuarial survival was seen between age groups. The association of young age at diagnosis with a worse prognosis in this series is explained by a higher proportion of poorly differentiated cancers; age itself had no influence on the prognosis of the individual.
There is a general perception that young age at diagnosis of breast cancer is associated with a poor prognosis (Earley et al, 1969; Brightmore et al, 1970; Noyes et al, 1982; Adami et al, 1986; Host and Lund, 1986; Ries et al, 1991; Sant et al, 1991; De La Rochefordiere et al, 1993; Bonnier et al, 1995) . However, other studies suggest that patients who develop breast cancer at a young age have a similar prognosis to older patients and that management of young breast cancer patients is best dictated by standard clinical and histopathological criteria (Birks et al, 1973; Gogas and Skalkeas, 1975; Wallgren et al, 1977; Rosen et al, 1984; Backhouse et al, 1987; Barchielli et al, 1994) .
The aims of this study were to assess prognostic factors and survival in young women diagnosed with operable primary invasive breast cancer and to compare these with cancers in older patients. Between 1973 Between and 1993 Between , 2879 patients aged < 70 years underwent surgery for primary operable breast cancer (< 5 cm clinical diameter) . Patients were categorized according to three defined age groups. One hundred and twenty (4%) were aged < 35 years at diagnosis (age group I), 1003 (35%) were aged 35-50 years (age group II) and 1756 (61%) were aged 51-70 years (age group III). Of patients aged < 35 years at the time of diagnosis, three were aged < 25 (2%), 32 were aged [25] [26] [27] [28] [29] (26%) and 85 were aged 30-34 years (72%).
PATIENTS AND METHODS

Surgical treatment
Surgery consisted of breast conservation (lumpectomy + intact breast radiation) or mastectomy with node sampling for invasive cancers. A triple node sampling procedure was performed until February 1988 (Du Toit et al, 1990 . Nodes were sampled from the lower axilla, the apex of the axilla and the internal mammary chain. The current policy for node staging at the Nottingham Breast Unit is for axillary node sampling of four or more nodes. Internal mammary node sampling is also performed for tumours located in the medial part of the breast. In 1988, we published details of histological risk factors associated with an increased risk of local recurrence after breast conservation for breast cancer (Locker et al, 1989) . Since then, patients whose tumours displayed such factors were recommended conversion to mastectomy. Patients with in situ ductal carcinoma (DCIS) only were treated by mastectomy or wide local excision. No patients with DCIS underwent a nodal staging procedure or received adjuvant radiotherapy.
Histopathology
Tumour size (cm) and lymph node stage (A, B or C) were known for all patients with invasive breast cancer. The stratification of lymph node stage for patients who underwent triple node biopsy depends on the level of axillary node involvement and/or involvement of the internal mammary chain and has been previously reported by our unit (Du Toit et al, 1990 ). Using our current staging system, node-negative disease is stage A, involvement of 1-3 axillary nodes or involvement of the internal mammary node chain is stage B and involvement of four or more axillary nodes or involvement of both axillary and internal mammary nodes is stage C. Histological tumour grade was determined using the method described by Elston and Ellis (1991) . Tumour type was assessed using standard criteria (Page and Anderson, 1987; Ellis et al, 1992) . Vascular invasion (VI) was classified as definite only if tumour cell emboli were noted within an endothelium-lined vascular or lymphatic space (Pinder et al, 1994) .
Previous studies from the Nottingham Breast Unit have shown that invasive tumour size, histological grade and lymph node stage are independent prognostic indicators for breast cancer specific survival (Haybittle et al, 1982 : Galea et al, 1992 . These three histological factors are used to determine the Nottingham Prognostic Index (NPI), which identifies three different prognostic groups (good prognostic group, GPG; moderate prognostic group, MPG; poor prognostic group, PPG) in terms of breast cancer specific survival. The NPI is based on actuarial survival data from 1664 patients aged < 70 years who received local and regional treatment for primary operable invasive breast cancer < 5 cm in size between 1973 and 1988 . No patients received adjuvant systemic therapy. Patients with in situ breast cancer are excluded from analyses usi-ng the NPI. The NPI is calculated using the following equation: NPI = 0.2 x tumour size (cm) + grade (1 -3) + lymph node score (1-3 according to stage A-C). A score of < 3.4
gives a good prognosis, 3.41-5.4 a moderate prognosis and > 5.4 a poor prognosis.
The NPI was calculated for all patients with invasive breast cancer in all three age groups for this study.
Adjuvant systemic therapy
Patients were not routinely given adjuvant systemic therapy before October 1988. Thereafter systemic therapy was given to all patients with NPI > 5.4 (poor prognostic group). Our current protocol is to offer adjuvant systemic therapy to all patients in the medium and poor prognosis groups. Post-menopausal patients with oestrogen receptor (ER)-positive tumours are treated with tamoxifen for 5 years. Patients with ER-negative tumours are offered chemotherapy using cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for 6 months or tamoxifen for 5 years.
Premenopausal patients with ER-negative tumours are treated with CMF for 6 months. Those with ER-positive tumours are offered CMF for 6 months or randomization to the Zeneca Zebra Study 118630/2802 which compares CMF for 6 months with monthly Zoladex injections for 2 years in premenopausal node-positive breast cancer patient;. The number of patients who received adjuvant systemic therapy according to age groups is shown in Table 1 .
Survival
Patients were reviewed at 3-monthly intervals for 2 years, 6-monthly to 5 years and annually thereafter. Follow-up for this group of patients was between 3 and 20 years. Survival curves for metastasis disease-free interval and actuarial survival for the three age groups were constructed using the life table analysis method and differences between groups were calculated using the modification of the Wilcoxon rank test (Lee Desu statistic) (Mantel, 1966) . The prognostic significance of age(< 35 years, 35-70 years) was also assessed by being entered into a Cox multivariate model (Cox, 1972) together with the known independent prognostic discriminants invasive tumour size (< 2 cm, 2-5 cm), histological tumour grade (1-3) and lymph node stage (A-C). (1997) 75(9), 1318-1323 Figure 2 Actuarial survival curves for age group (*, age < 35 years), group 11 (Ol, age 35-50 years) and group III (A, age 51-70 years). %2 = 6.6. P = 0.03 (2 d.f.) per annum (Forrest, 1987) . This means that the average incidence of breast cancer between ages 25 and 34 in this series is 1.1 per 10 000 per annum.
Several studies have shown that early age at diagnosis is associated with histological tumour characteristics, suggesting an aggressive breast cancer phenotype (Earley et al, 1969; Wallgren et al, 1977; Rosen et al, 1984; Remvikos et al, 1995) . In this series, patients diagnosed with breast cancer at age < 35 years were more likely to have high-grade tumours exhibiting vascular invasion. l-----l, PPG for patient age < 35 years (n = 34). Within any one NPI group, no difference is seen according to age
The young age group were less likely to have lobular carcinomas or well-differentiated 'special type' cancers, which are associated with a survival advantage compared with ductal carcinomas of no special type (Ellis et al, 1992) . Several studies have suggested that medullary and atypical medullary carcinomas are more common in young patients (Gogas and Skalkeas, 1975; Rosen et al, 1985; Claus et al, 1993) . This also occurred in our series. An excess proportion of medullary and atypical medullary cancers has recently been reported in young women with BRCAlrelated hereditary breast cancer (Marcus et al, 1996) . The association of these two tumour types in patients with sporadic early-onset breast cancer could denote the presence of a breast cancer susceptibility gene mutation. Although it has been suggested that medullary carcinoma carries a good prognosis (Ridolfi et al, 1977) , we have previously reported that neither medullary carcinoma nor atypical medullary carcinoma have a survival advantage over ductal carcinomas of no special type (Ellis et al, 1992) . Rosen et al (1984) found 8% of patients diagnosed with breast cancer at age < 35 years to have in situ disease. In this series, 8% of cancers diagnosed in women aged < 35 years were non-invasive. However, the percentage of patients with DCIS was similar within the three age groups (6-8%).
Tumour size did not differ between age groups in this series. No differences in lymph node status were demonstrated between age groups. These findings are similar to those of other series which showed no differences in lymph node involvement between young patients and older age groups (Mueller et al, 1978; Rosen et al, 1984 Lund, 1986; Sant et al, 1991) and clinical studies (Earley et al, 1969; Noyes et al, 1982; Ries et al, 1991; De La Rochefordiere et al, 1993; Bonnier et al, 1995) have shown early age at diagnosis to be an adverse factor affecting prognosis. Others have shown no survival difference between age groups (Birks et al, 1973; Gogas and Skalkeas, 1975; Wallgren et al, 1977; Rosen et al, 1984; Backhouse et al, 1987; Barchielli et al, 1994) . The results of this study using a large patient cohort with long-term follow-up have shown a significant difference in metastasis disease-free survival and actuarial survival between young breast cancer patients and two older age groups with primary operable invasive breast cancer. This is entirely explained by a significantly higher proportion of young patients having biological tumour characteristics, such as high grade and vascular invasion, which are associated with a worse prognosis (Elston and Ellis, 1991; Pinder et al, 1994) . This results in more young patients lying within the poor prognostic group. No differences were seen when survival between age groups was compared according to the three Nottingham prognostic groups. Survival in young breast cancer patients was exactly as predicted by their prognostic index. This was confirmed by the results of the Cox multivariate analysis which failed to demonstrate young age as an independent prognostic indicator when compared to the three histological factors that comprise the NPI. The results of this study differ from those of a recent study by Bonnier et al (1995) which suggested that young age was an independent prognostic indicator after using a Cox model.
Discrepancies in the results of the two studies may be explained by the small number of early-onset cases used to fit the Cox model in Bonnier's study, which may not be representative of the group as a whole. Furthermore, the Bloom and Richardson histological grading system used in that study is often criticized for being too subjective. Because histological tumour grading is a strong prognostic indicator, inconsistencies in a grading system will have a marked effect on other factors used in a multivariate analysis. The semiquantitative grading system proposed by Elston and Ellis (1991) has been shown by other centres to be reproducible with little interobserver variability (Dalton et al, 1994; Cummings et al, 1995; Frierson et al, 1995) . No differences were seen in the proportion of patients in the moderate and poor prognosis groups who received adjuvant systemic therapy according to age groups. Therefore, the effect of adjuvant systemic therapy is not expected to contribute to the differences seen in actuarial survival.
Young age alone is not an independent prognostic variable in primary breast cancer. However, adverse intrinsic biological factors are more likely to be found in breast cancers of young women.
